132 related articles for article (PubMed ID: 36442383)
1. Patient-Reported Distress and Clinical Outcomes with Immuno-Oncology Agents in Metastatic Non-Small Cell Lung Cancer (mNSCLC): A Real-World Retrospective Cohort Study.
Bodd MH; Locke SC; Wolf SP; Antonia S; Crawford J; Hartman J; Herring KW; Ready NE; Stinchcombe TE; Troy JD; Williams C; Clarke JM; LeBlanc TW
Lung Cancer; 2023 Jan; 175():17-26. PubMed ID: 36442383
[TBL] [Abstract][Full Text] [Related]
2. Real-World Costs of Adverse Events in First-Line Treatment of Metastatic Non-Small Cell Lung Cancer.
Engel-Nitz NM; Johnson MP; Bunner SH; Ryan KJ
J Manag Care Spec Pharm; 2020 Jun; 26(6):729-740. PubMed ID: 32463768
[TBL] [Abstract][Full Text] [Related]
3. STK11 (LKB1) mutations in metastatic NSCLC: Prognostic value in the real world.
Shire NJ; Klein AB; Golozar A; Collins JM; Fraeman KH; Nordstrom BL; McEwen R; Hembrough T; Rizvi NA
PLoS One; 2020; 15(9):e0238358. PubMed ID: 32881920
[TBL] [Abstract][Full Text] [Related]
4. Patient-reported distress as an early warning sign of unmet palliative care needs and increased healthcare utilization in patients with advanced cancer.
Hildenbrand JD; Park HS; Casarett DJ; Corbett C; Ellis AM; Herring KW; Kamal AH; Power S; Troy JD; Wolf S; Zafar SY; Leblanc TW
Support Care Cancer; 2022 Apr; 30(4):3419-3427. PubMed ID: 34997315
[TBL] [Abstract][Full Text] [Related]
5. Health outcomes and healthcare resource utilization among Veterans with stage IV non-small cell lung cancer treated with second-line chemotherapy versus immunotherapy.
Williams CD; Allo MA; Gu L; Vashistha V; Press A; Kelley M
PLoS One; 2023; 18(2):e0282020. PubMed ID: 36809528
[TBL] [Abstract][Full Text] [Related]
6. Real-World Outcomes of Patients with Metastatic Non-Small Cell Lung Cancer Treated with Programmed Cell Death Protein 1 Inhibitors in the Year Following U.S. Regulatory Approval.
Khozin S; Carson KR; Zhi J; Tucker M; Lee SE; Light DE; Curtis MD; Bralic M; Kaganman I; Gossai A; Hofmeister P; Torres AZ; Miksad RA; Blumenthal GM; Pazdur R; Abernethy AP
Oncologist; 2019 May; 24(5):648-656. PubMed ID: 30591549
[TBL] [Abstract][Full Text] [Related]
7. Patient-Reported Outcomes From Patients Receiving Immunotherapy or Chemoimmunotherapy for Metastatic Non-Small-Cell Lung Cancer in Clinical Practice.
Steffen McLouth LE; Lycan TW; Levine BJ; Gabbard J; Ruiz J; Farris M; Grant SC; Pajewski NM; Weaver KE; Petty WJ
Clin Lung Cancer; 2020 May; 21(3):255-263.e4. PubMed ID: 31917067
[TBL] [Abstract][Full Text] [Related]
8. Comparison of demographics, treatment patterns, health care utilization, and costs among elderly patients with extensive-stage small cell and metastatic non-small cell lung cancers.
Karve SJ; Price GL; Davis KL; Pohl GM; Smyth EN; Bowman L
BMC Health Serv Res; 2014 Nov; 14():555. PubMed ID: 25392276
[TBL] [Abstract][Full Text] [Related]
9. Hospitalizations During Systemic Therapy for Metastatic Lung Cancer: A Systematic Review of Real World vs Clinical Trial Outcomes.
Prince RM; Atenafu EG; Krzyzanowska MK
JAMA Oncol; 2015 Dec; 1(9):1333-9. PubMed ID: 26378774
[TBL] [Abstract][Full Text] [Related]
10. Biomarker Testing, Treatment, and Outcomes in Patients With Advanced/Metastatic Non-Small Cell Lung Cancer Using a Real-World Database.
Bhandari NR; Hess LM; He D; Peterson P
J Natl Compr Canc Netw; 2023 Sep; 21(9):934-944.e1. PubMed ID: 37673115
[TBL] [Abstract][Full Text] [Related]
11. Characterization of ERBB2 (HER2) Alterations in Metastatic Non-small Cell Lung Cancer and Comparison of Outcomes of Different Trastuzumab-based Regimens.
Waliany S; Wakelee H; Ramchandran K; Das M; Huang J; Myall N; Li C; Pagtama J; Tisch AH; Neal JW
Clin Lung Cancer; 2022 Sep; 23(6):498-509. PubMed ID: 35753988
[TBL] [Abstract][Full Text] [Related]
12. Understanding total cost of care in advanced non-small cell lung cancer pre- and postapproval of immuno-oncology therapies.
Korytowsky B; Radtchenko J; Nwokeji ED; Tuell KW; Kish JK; Feinberg BA
Am J Manag Care; 2018 Oct; 24(20 Suppl):S439-S447. PubMed ID: 30362811
[TBL] [Abstract][Full Text] [Related]
13. Outcomes of patients with solid tumour malignancies treated with first-line immuno-oncology agents who do not meet eligibility criteria for clinical trials.
Gan CL; Stukalin I; Meyers DE; Dudani S; Grosjean HAI; Dolter S; Ewanchuk BW; Goutam S; Sander M; Wells C; Pabani A; Cheng T; Monzon J; Morris D; Basappa NS; Pal SK; Wood LA; Donskov F; Choueiri TK; Heng DYC
Eur J Cancer; 2021 Jul; 151():115-125. PubMed ID: 33975059
[TBL] [Abstract][Full Text] [Related]
14. First-line treatment of advanced epidermal growth factor receptor (EGFR) mutation positive non-squamous non-small cell lung cancer.
Greenhalgh J; Boland A; Bates V; Vecchio F; Dundar Y; Chaplin M; Green JA
Cochrane Database Syst Rev; 2021 Mar; 3(3):CD010383. PubMed ID: 33734432
[TBL] [Abstract][Full Text] [Related]
15. Treatment Patterns and Clinical Outcomes Among Metastatic Non-Small-Cell Lung Cancer Patients Treated in the Community Practice Setting.
Nadler E; Espirito JL; Pavilack M; Boyd M; Vergara-Silva A; Fernandes A
Clin Lung Cancer; 2018 Jul; 19(4):360-370. PubMed ID: 29576407
[TBL] [Abstract][Full Text] [Related]
16. Better together? costs of first-line chemoimmunotherapy for advanced non-small cell lung cancer.
Kish J; Liassou D; Hartman J; Lubinga SJ; Chopra D; Feinberg B
Am J Manag Care; 2023 May; 29(5):e129-e135. PubMed ID: 37229786
[TBL] [Abstract][Full Text] [Related]
17. Real-world treatment patterns and costs in a US Medicare population with metastatic squamous non-small cell lung cancer.
Davis KL; Goyal RK; Able SL; Brown J; Li L; Kaye JA
Lung Cancer; 2015 Feb; 87(2):176-85. PubMed ID: 25532680
[TBL] [Abstract][Full Text] [Related]
18. Association of a novel 27-gene immuno-oncology assay with efficacy of immune checkpoint inhibitors in advanced non-small cell lung cancer.
Ranganath H; Jain AL; Smith JR; Ryder J; Chaudry A; Miller E; Hare F; Valasareddy P; Seitz RS; Hout DR; Varga MG; Schweitzer BL; Nielsen TJ; Mullins J; Ross DT; Gandara DR; Vidal GA
BMC Cancer; 2022 Apr; 22(1):407. PubMed ID: 35421940
[TBL] [Abstract][Full Text] [Related]
19. Comparison of real-world data (RWD) analysis on efficacy and post-progression outcomes with pembrolizumab plus chemo vs chemo alone in metastatic non-squamous non-small cell lung cancer with PD-L1 < 50.
Attili I; Valenza C; Santoro C; Antonarelli G; Trillo Aliaga P; Del Signore E; Catania C; Spitaleri G; Passaro A; de Marinis F
Front Oncol; 2022; 12():980765. PubMed ID: 36033444
[TBL] [Abstract][Full Text] [Related]
20. Patient-Reported Distress in Myelodysplastic Syndromes and Its Association With Clinical Outcomes: A Retrospective Cohort Study.
Troy JD; de Castro CM; Pupa MR; Samsa GP; Abernethy AP; LeBlanc TW
J Natl Compr Canc Netw; 2018 Mar; 16(3):267-273. PubMed ID: 29523665
[No Abstract] [Full Text] [Related]
[Next] [New Search]